A comprehensive review discusses how ctDNA and immune biomarkers such as mismatch repair deficiency, microsatellite instability, and tumor mutational burden can identify patients at high risk of recurrence and guide adjuvant treatment decisions. (Frontiers in Medicine)
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
The CRC Digest